Aerosol Generation

Aerosol Drug Delivery

Aerosol Delivery of Biotherapeutics

Inhalation Toxicology

 

 

News Release

June 1, 2017

Dr. Yeates to present: "Augmentation of the Generation, Processing and Delivery of Surfactant and Macromolecule Aerosols with Heliox", 21 ISAM-Congress, Santa Fe, NM, June 3-7, 2017.

ISAM

 

 

 

May 3, 2017

KAER, a Start-Up Breakthrough Finalist, will be presenting at Start-Up Stadium, BIO, San Diego, June 21, 2017 (convention.bio.org/startup/)

BIO Finalist

 

 

October 2016

Dr. Yeates to present: "Aerosol Surfactant Replacement Therapy for Patients with Acute Respiratory Distress Syndrome" at the Life Sciences Summit, New York, NY, November 2-3, 2016.LifeSciense

 

 

Dr. Yeates to present: "Generation of Respirable Particles from Surfactant Suspensions and Viscous Solutions at High Dose Rates", Drug Delivery to the Lungs, Edinburgh, UK, December 7-9, 2016.

 

April 30, 2016

A potential new treatment for Acute Respiratory Distress Syndrome and Acute Lung Injury (ARDS/ALI) has been developed using an aerosolized surfactant. KAER has incorporated a new patent-pending nozzle technology into its SUPRAER® aerosol delivery platform. For the first time, surfactant aerosols less than 4 microns in diameter, can be delivered at 2 mg/second. In conjunction with negative pressure ventilation or incorporation of this technology into a ventilator would facilitate the delivery of a therapeutically-needed 1 g of surfactant aerosol to the patient’s deep lung in 20 minutes. This surfactant is targeted at replacing the inflammation-induced inactivated surfactant in these critically ill patients and reversing the resultant hypoxemia by reducing the surface tension in the deep lung, opening alveoli, resolving excess lung fluid (edema), decreasing the work of breathing, and thus improving gas exchange. KAER is working toward reducing the present mortality of these syndromes to considerably less than the current 43%.

The SUPRAER technology can be used to aerosolize viscous solutions and suspensions of any drug. Using 20% solutions of polyvinylpyrrolidone, as a protein or drug surrogate, aerosols of less than 4 microns in diameter have been generated at output rates up to 4 mg/second. A typical 7-second inhalation would deliver up to 28 mg during each breath or a therapeutically-needed dose of up to 280 mg in just 10 breaths. This is game-changing for the rapid delivery of anti-infectives and anticancer agents to the lungs.

The final size of these drug aerosol particles can be tailored for optimum deposition in the lungs of small and large animals as well as humans. These new developments add to KAER’s worldwide intellectual property portfolio on aerosol generation and processing for respiratory drug delivery. A comprehensive set of data generated with KAER’s new nozzles incorporated into the SUPRAER platform was presented at the Respiratory Drug Delivery conference in Phoenix, AZ, April 18-19, 2016. e April 30, 2016

 

 

March 14, 2016

KAER exhibited at the Society of Toxicology in New Orleans, March 14-16, 2016.

 

November 15, 2015

KAER is a finalist for a 2016 Patrick Soon Shiong Innovation Award for its SUPRAER aerosol delivery technology.


September 1, 2015

National Heart Lung and Blood Institute of the National Institutes of Health award KAER Biotherapeutics a Phase I SBIR grant “Aerosol delivery of Surfactant for ARDS” commencing September 1, 2015. 


Acute respiratory distress syndrome, ARDS, including acute lung injury ALI are of multifactorial etiology and afflicts 190,000 Americans each year and 18% of all ventilated patients. Despite sophisticated intensive care, the mortality rate ranges between 15 and 72% with a mean of 43%.  Patients with ARDS have impaired surfactant function and continued inflammation-induced metabolism of surfactant indicating that a single treatment with surfactant is inadequate. Our target is to demonstrate that using KAER’s SUPRAER technologies, clinically relevant doses of surfactant aerosols can be generated and delivered within a short treatment period.  The delivery of surfactant in a gentler, non-invasive manner would empower the clinician to provide improved life support and potentially a marked improvement in survival.

Dr. Yeates, Principal Investigator of this project noted, “This important new technological innovation will also be applicable to treat other diseases of the lungs that require drugs whose efficacy depends on high doses being delivered in a short time.  Short treatment times lead to better patient adherence, efficacy and improved heath care.”

 

October 13, 2015

KAER exhibited at the Association of Inhalation Toxicologist, Cambridge, UK, Oct 13-15, 2015.

March 20, 2015

KAER exhibited at the Society of Toxicology, San Diego, March 20-23 2015.

 

Nov 18-20,2014

Dr. Yeates presented "Aerosol delivery of Biotherapeutics:New Technologies" at Drug Delivery Systems 2014, Suzhou, China.

 

September 22-24, 2014

KAER exhibited at the AIT-ISAM joint conference "Inhaled Medications from the Bench to the Bedside: Preclinical, Clinical and Technical Considerations for 'First in Human' and Beyond" Princeton, NJ, 2014.

 

May 4-8, 2014

KAER exhibited at the Respiratory Drug Delivery, Puerto Rico.

 

March 23-25, 2014

KAER exhibited at the Society of Toxicology Annual Meetin in Phoenix

September 11-12, 2013

Dr. Yeates presented, "A New Class of Aerosol Generation System for High Dose-Rate Aerosol Delivery of Biotherapeutics" at: Inhalation Drug Delivery, Berlin, Germany.

Logo for CHpi

 

 

 

 

June 11, 2013

KAER presented at NHLBI San Diego Innovation Conference, San Diego, CANIHLBI logo


 

May 21, 2013

Dr. Yeates presented a poster "High Dose Rate generation of fine particle aerosols of antibodies with SUPRAER compared to two mesh-type nebulizers." at Respiratory Drug Delivery in Berlin. RDD E

 

 

April 20-23, 2013

KAER exibited at the ISAM conference in Chapel Hill, N. Carolina and Donovan Yeates presented the poster "Generation of Respirable Antibody Aerosols". ISAM 2013 logo

 

 

 

March 12, 2013

Frost & Sullivan present to Donovan Yeates, CEO of KAER, the 2012 North American Technology Innovation Award for Aerosol Drug Delivery. To see Frost & Sullivan's news release on Yahoo click here

Dr. Yeates receives Award

In recognition of SUPRAER’s technology and its importance in the drug delivery industry, Frost and Sullivan awarded KAER Biotherapeutics their 2012 North American Technology Innovation Award for Aerosol Drug Delivery. This award was based on metrics from 1 to 10 quantifying the following criteria: uniqueness of technology, new products/applications, impact on functionality, impact on customer value, and relevance of innovation to industry. The two top competitors average score was 5 and 4, whereas SUPRAER’s average score was 10. Request copy of full report

 

March 11-13, 2012

KAER Biotherapeutics exibited SUPRAER at the 2013 Society of Toxicology Conference in San Antonio.

Oct 16-17, 2012

KAER Biotherapeutics was presented by Dr. Yeates at IN3 medical Device Summit in San Francisco . http://www.in3summit.com

May 13-17, 2012

Dr. Yeates presented "SUPRAER: A PLATFORM FOR HIGH DOSE RATE DELIVERY OF BIOTHERAPEUTICS" at Respiratory Drug Delivery, Phoenix, AZ.

March, 11-15, 2012

Dr. Yeates Presented "COMPACT HIGH OUTPUT RESPIRABLE AEROSOL GENERATOR FOR BIOLOGICS" at Society of Toxicology, San Francisco, CA .

January 9-13, 2012

Dr. Yeates presented "New System for the Generation and Delivery of High Concentrations of Respirable Aerosols of Biologics and Large Labile Molecules at PepTalk in the Spray Drying and Emerging Technologies session, San Diego, CA.

Nov 3-5 2011

Dr. Yeates presented "SUPRAER: A New Aerosol Delivery Platform for High Dose-Rate Delivery of Biotherapeutics" in the Pulmonary Drug Delivery session of Drug Delivery Systems in Shenzhen, China.

June 18-21, 2011

SUPRAER was launched at the International Society for Aerosols in Medicine in Rotterdam, NL.

 

 

 

Copyright KAER Biotherapeutics Corporation. All Rights Reserved